Please ensure Javascript is enabled for purposes of website accessibility

Juno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration

By Keith Speights – May 5, 2017 at 11:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage biotech posts much higher top-line results in Q1 with an influx in cash from its big partner, Celgene.

When Juno Therapeutics (JUNO) announced its fourth-quarter and full-year 2016 results in March, investors were most focused on the company's discontinuation of development of a once-promising lead cancer drug. Juno chose to refocus on its other pipeline candidates after patient deaths occurred in clinical studies of JCAR015.

Juno provided its first-quarter 2017 update after the market closed on Thursday. JCAR015 wasn't a topic of discussion this time around. Much more important was Juno's relationship with big partner Celgene (CELG). Here are the highlights.


Image source: Getty Images.

Juno Therapeutics results: The raw numbers


Q1 2017 

Q1 2016 

Year-Over-Year Change


 $19.3 million  $9.8 million


Net income from continuing operations

 ($82.2 million)  ($71.1 million)


Adjusted net loss per share

 ($0.71)  ($0.78)


Data source: Juno Therapeutics. 

What happened with Juno Therapeutics this quarter?

Juno's revenue nearly doubled in the first quarter of 2017 compared to the prior-year period. This increase stemmed largely from the company's collaboration with Celgene. In April 2016, Celgene exercised its option to develop and commercialize Juno's CD19 program. The big biotech paid Juno $50 million and shares in all development costs of the program.

The bigger net loss in the first quarter was a result of increased operating expenses. Juno's research and development costs rose 12.5% year over year to $82.9 million. First-quarter general and administrative costs increased 30% year over year to $20.7 million.

Juno's non-GAAP net loss improved compared to the prior-year period, though. The better results were primarily thanks to a change in the estimated fair value of the success payment obligations owed to Memorial Sloan Kettering Cancer Center and the Fred Hutchinson Cancer Research Center.

The most important financial results for Juno in the first quarter related to its cash position and cash burn. Juno reported cash, cash equivalents, and marketable securities totaling $850.7 million at the end of the first quarter, down from $922.3 million at the end of 2016. Its cash burn in the first quarter, excluding cash inflows and outflows from business development activities, was $75.3 million.

Juno's cash burn in the first quarter 2017 increased from the $61 million recorded in the prior-year period. This increase stemmed from general growth in the biotech's clinical, manufacturing, and research operations (including purchase of manufacturing equipment) as well as additional costs to build out Juno's planned headquarters facility. However, the cash burn increase was partially offset by $11.2 million received from Celgene during the first quarter.

What management had to say

Juno Therapeutics president and CEO Hans Bishop said, "In the first quarter 2017, we made significant progress with our lead program, JCAR017, and we look forward to presenting updated data in DLBCL at ASCO."

Bishop added:

We also continue to advance our pipeline more broadly with eleven product candidates now in human testing. Already this year, we have initiated a number of trials, including a BCMA CAR T, a CD19-directed 4-1BBL armored CAR, a fully human CD19 CAR T, a combination trial with JCAR014 and durvalumab, and a combination trial with JCAR014 and ibrutinib. With up to 20 ongoing trials by year end, we expect to gain additional insights that may lead to product candidates that can deliver long-term durable remissions for patients in need.

Looking forward

Juno continues to expect cash burn in 2017, excluding cash inflows or outflows from upfront payments related to business development activities, of between $270 million and $300 million. The company should still have an excellent cash position for a while to come.

With JCAR015 out of the picture, Juno's hopes rest largely on another CD19 candidate, JCAR017. The company is evaluating JCAR017 in a phase 1 study for treating in non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Juno also plans to seek approval to begin clinical testing for JCAR017, or a similar candidate, in treating chronic lymphocytic leukemia (CLL). 

If everything goes well, Juno could potentially be in position to obtain regulatory approval for JCAR017 in treating DLBCL as early as 2018, and in treating CLL as early as 2019. There is a long way to go before the company will be in position to seek regulatory approval, but investors have much to watch along the way.

Keith Speights owns shares of Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Juno Therapeutics Inc. Stock Quote
Juno Therapeutics Inc.
Celgene Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.